Search clinical trials for: Platinum Refractory Extensive-Stage Small Cell Lung Cancer

Total 161356 results

NiKang Therapeutics, Inc.

Recruiting

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Small Cell Lung Carcinoma | Gastric Cancer | Ovarian Neoplasms | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Solid... and other conditions

United States
Amgen

Not yet recruiting

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

Small-Cell Lung Cancer | Extensive-Stage Small-Cell Lung Cancer
Trans Tasman Radiation Oncology Group
AstraZeneca

Recruiting

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy (CHEST RT)

Extensive-Stage Small-Cell Lung Cancer

Australia
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (TOASTIT)

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Rhabdomyosarcoma | Refractory Rhabdomyosarcoma | Recurrent Colon Carcinoma | Recurrent Gastric Carcinoma | Recurrent Rectal Carcinoma | Refractory Sarcoma | Refractory Ovarian Carcinoma | Resectable... and other conditions

United States
Case Comprehensive Cancer Center

Recruiting

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Small-cell Lung Cancer | Large Cell Neuroendocrine Carcinoma of the Lung | Extrapulmonary Small Cell Carcinoma

United States
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Completed

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer | Extensive-stage Small Cell Lung Cancer

United States
AbbVie

Terminated

A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU)

Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lit... and more
University of Alabama at Birmingham
Boehringer Ingelheim

Completed

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Renal Cell Carcinoma | Non-squamous Non-small Cell Lung Cancer | Cervical Carcinoma | Colorectal Adenocarcinoma | Platinum-refractory Ovarian Carcinoma

United States
Intergroupe Francophone de Cancerologie Thoracique

Completed

Stage I/II NSCLC Perioperative Chemotherapy

Non-small Cell Lung Cancer Stage I and II | Peri-operative Chemotherapy

France
National Cancer Institute, Naples

Terminated

The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer (DISTAL-2)

Advanced Non-Small Cell Lung Cancer

Italy
European Lung Cancer Working Party

Completed

A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

Small Cell Lung Carcinoma

Belgium
Taiho Oncology, Inc.
Taiho Pharmaceutical Co., Ltd.

Terminated

A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Small Cell Lung Cancer (SCLC)

Japan, Italy, Germany
University of Michigan Rogel Cancer Center

Completed

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

Extensive-Stage Small Cell Lung Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Lung Cancer

Canada, United States
National Cancer Institute (NCI)

Completed

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
GlaxoSmithKline

Completed

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States, Belgium, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Poniard Pharmaceuticals

Completed

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Canada, Russian Federation
Henan Cancer Hospital

Not yet recruiting

Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer NSCLC
University Hospital, Lille
Exeliom Biosciences

Not yet recruiting

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. (EXLIBRIS)

Non-Small Cell Lung Cancer
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) (neoR-TORCH)

Stage II-III Non-small Cell Lung Cancer
Zeng Jian

Recruiting

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Shanghai Simnova Biotechnology Co.,Ltd.
Shanghai Chest Hospital

Recruiting

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Centro di Riferimento Oncologico - Aviano

Recruiting

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL)

Non Small Cell Lung Cancer Metastatic | ALK Gene Mutation

Italy
Fudan University

Recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain, Turkey
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Limited Stage Small Cell Lung Cancer

China
MacroGenics

Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

Melanoma | Sarcoma | Clear Cell Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Advanced Solid Tumor | Endometrial Cancer | Small-cell Lung Cancer | Advanced... and other conditions

United States
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Esophageal Carcinoma | Lung Cancer, Nonsmall Cell

China
Georgetown University
MacroGenics

Recruiting

MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (MGC018-SCLC)

Extensive-stage Small-cell Lung Cancer

United States
NovoCure GmbH

Not yet recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)

Metastatic Non-small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy...
Dizal Pharmaceuticals

Not yet recruiting

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (JACKPOT33)

Non-Small-Cell Lung Cancer

China
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Peking Union Medical College Hospital

Not yet recruiting

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Non Small Cell Lung Cancer | Immune Checkpoint Inhibitor | EGFR Exon 21 Mutation

China
LI YAN

Not yet recruiting

Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression

Non-small Cell Lung Cancer
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Non-Small Cell Lung Cancer
Bristol-Myers Squibb

Recruiting

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NSCLC

United States, Argentina, Chile, France, Italy, Poland, Romania, Spain, Australia
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
Georgetown University
Bristol-Myers Squibb; Targovax ASA; Janssen, LP

Recruiting

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (DARANIVOVAX)

Pancreatic Ductal Adenocarcinoma | Refractory Non-Small Cell Lung Cancer

United States
STCube, Inc.

Recruiting

A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

United States, Korea, Republic of

Search clinical trials for: Platinum Refractory Extensive-Stage Small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations